globenewswire.com · 17 jul

Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations

BRIDGEWATER, N.J., July 17, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced that it has received U.S. Food and Drug Administration (FDA) approval for additional strengths and vial presentations of iohexol injection, 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, as well as 300 mg iodine/mL in 50 mL vial. Amneal plans to launch these products in the third quarter of 2026.

globenewswire.com · 9 jul

Amneal to Report Second Quarter 2026 Results on July 30, 2026

BRIDGEWATER, N.J., July 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report second quarter 2026 financial results on Thursday, July 30, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET.

zacks.com · 2 jul

Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

globenewswire.com · 29 jun

Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations

MILAN and BRIDGEWATER, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Zambon and Amneal Pharmaceuticals today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson's disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens.

zacks.com · 24 jun

Why Amneal Pharmaceuticals (AMRX) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

forbes.com · 17 jun

The Healthcare M&A Wave

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

zacks.com · 11 jun

AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?

Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

gurufocus.com · 10 jun

Is Amneal Pharmaceuticals Inc (AMRX) Overvalued After 4.4% Rally? GF Value Says Overvalued

On June 10, 2026, Amneal Pharmaceuticals Inc (AMRX) shares rose 4.4% today, bringing the current price to $15.32. This price is within a 52-week range that has